| inbluevt | Date: Monday, 2013/10/14, 6:07 PM | Message # 1 | DMCA |
|
|
Private
Group: Blocked
Messages: 1024
|
MEXICO CITY, Oct 8 2013 (IPS) - The Trans Pacific Partnership Agreement (TPP), the negotiation of which is set to conclude this year, could drive research into new drugs and improve access to medicines. Except – it won’t.
“The current health system is reaching its limit,” Judit Rius, manager of Médecins Sans Frontières/Doctors Without Borders Access Campaign in the United States, told IPS. “It is
failing patients with rare diseases, for example.”
“That’s why the TPP could be a tool for promoting health and improving innovation and access, instead of fostering failed, costly systems based on monopolistic patents,” she added.
The TPP free trade accord went into force between Brunei, Chile, New Zealand and Singapore in January 2006. Eight other countries are now negotiating their incorporation: Australia, Canada, Japan, Malaysia, Mexico, Peru, the United States and Vietnam. Of the 29 chapters under negotiation, the ones on intellectual property, investment and government procurement contain proposals, especially from the United States, to limit research and development of generic
medicines, which are sold with the name of the active ingredient and can be produced once the patent for the original brand-name drug has expired.
Because they are less expensive, generic drugs are essential in the fight against disease, especially in poor developing countries.
The TPP talks have been shrouded in secrecy. But Rius said the aspects of the TPP that have been leaked to the press would hinder R&D in generic medicines, hurting the reduction of prices that has been achieved in recent years.
More
Critics: TPP could jack up drug costs - read
Message edited by inbluevt - Monday, 2013/10/14, 6:10 PM |
|
|
| |
Main 
